Ketamine for suicidal ideations in severe depression
Rakesh Garg, Gurmeet Kaur Brar, Manpreet K. Singh
Adesh University Journal of Medical Sciences & Research September 25, 2025 DOI: 10.25259/aujmsr_65_2025 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 38-year-old female with recurrent depressive disorder and active suicidal ideation |
| Intervention | Ketamine infusion |
| Topics | Depression Ketamine Esketamine |
| Keywords | Tolerability Antidepressant Depression economics Blockade Rating scale Depressive symptoms Suicidal ideation Anesthesia Nmda receptor Glutamatergic Mechanism biology Genetic neurodegenerative diseases |
| Key findings | A single ketamine infusion reduced HDRS score from 33 to 23 and decreased suicidal ideation in a patient with treatment-resistant depression. |
Abstract
This case report describes the management of a 38-year-old female with recurrent depressive disorder, who presented with severe depressive symptoms and active suicidal ideations. She reported persistent low mood, loss of interest in pleasurable activities, fatigue, and disturbed sleep for nearly three weeks, with recurrent thoughts of ending her life in the preceding week. Despite being on multiple psychotropic medications including lamotrigine, desvenlafaxine, mirtazapine, and benzodiazepines, her symptoms had worsened, warranting urgent intervention. On admission, her Hamilton Depression Rating Scale (HDRS) score was 33, indicating severe depression. In view of high suicidal risk and inadequate response to ongoing treatment, ketamine infusion was planned as a rapid-acting antidepressant strategy. Following the first session, her HDRS score reduced to 23, accompanied by a noticeable decline in suicidal ideations. This improvement highlights the potential of ketamine as a fast-acting therapeutic option in cases of severe depression with suicidality. Acting through NMDA receptor blockade and modulation of glutamatergic transmission, ketamine offers a novel mechanism distinct from conventional antidepressants. The case supports the growing evidence base for the use of ketamine in psychiatric emergencies where rapid symptom relief is critical and underscores its tolerability at sub-anesthetic doses.